FDA panel votes against ecstasy for PTSD

Source: Axios

“A Food and Drug Administration advisory panel on Tuesday overwhelmingly recommended against using the drug ecstasy combined with psychotherapy to treat PTSD, possibly derailing what would be the first psychedelic drug approval in the U.S. … The FDA does not have to follow the advice of its advisory committees but usually does. The agency is expected to make a final decision on whether to approve the drug application from Lykos Therapeutics by Aug. 11. Nine of 11 advisory panel members after a daylong meeting voted that the data do not show that the MDMA-assisted therapy is effective in treating PTSD.” (06/04/24)